2023
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, Agil D, Augenbraun M, Benning L, Horberg M, Jefferson C, Marconi V, Park L, Gordon K, Bastarache L, Gangireddy S, Althoff K, Coburn S, Gebo K, Lang R, Williams C, Silverberg M. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout. Clinical Infectious Diseases 2023, 76: 1727-1734. PMID: 36861341, PMCID: PMC10209434, DOI: 10.1093/cid/ciad084.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAdjusted risk ratioCOVID-19 hospitalizationMechanical ventilationTenofovir useHIV statusAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere coronavirus disease 2019 (COVID-19) outcomesSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) outcomesHuman immunodeficiency virus statusCohort of PWHCD4 cell countCharlson Comorbidity IndexCoronavirus 2 infectionHIV RNA levelsUnited States cohortBody mass indexCOVID-19 severityCOVID-19 vaccine availabilityReal-world analysisTenofovir exposureComorbidity indexMass indexDelirium among people aging with and without HIV: Role of alcohol and Neurocognitively active medications
Akgün K, Krishnan S, Tate J, Bryant K, Pisani M, Re V, Rentsch C, Crothers K, Gordon K, Justice A, team F. Delirium among people aging with and without HIV: Role of alcohol and Neurocognitively active medications. Journal Of The American Geriatrics Society 2023, 71: 1861-1872. PMID: 36786300, PMCID: PMC10258127, DOI: 10.1111/jgs.18265.Peer-Reviewed Original ResearchConceptsAlcohol Use Disorders Identification Test-ConsumptionActive medicationAlcohol useOdds ratioRelative riskDose-response associationDate of admissionSeverity of illnessIndependent dose-response associationsRace/ethnicityInpatient deliriumIndex dateMedication exposureRole of alcoholHIV statusMultivariable analysisMedication countNeurocognitive dysfunctionUnderappreciated causeDeliriumHigh incidencePWHMedicationsPWOHLogistic regressionFactors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use
Bahji A, Gordon K, Crystal S, Satre D, Wiliams E, Edelman E, Justice A. Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use. AIDS And Behavior 2023, 27: 2455-2462. PMID: 36622487, PMCID: PMC10225332, DOI: 10.1007/s10461-022-03972-3.Peer-Reviewed Original Research
2019
Predictors of timely opioid agonist treatment initiation among veterans with and without HIV
Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer KL. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug And Alcohol Dependence 2019, 198: 70-75. PMID: 30878769, PMCID: PMC6836871, DOI: 10.1016/j.drugalcdep.2019.01.038.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyOAT initiationUninfected patientsClinical encountersNational observational cohortAging Cohort StudyAfrican American patientsImproved health outcomesAgonist therapyCohort studyObservational cohortTreatment initiationPredictive factorsEffective treatmentAdjusted modelUninfected controlsUse disordersPsychiatric diagnosisPWHClinical practicePatientsHealth outcomesRural residence